David Sayah

Title: David Sayah: Innovator in Anti-Viral Research

Introduction

David Sayah is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of anti-viral research, particularly in the development of innovative nucleic acid technologies. With a total of 2 patents to his name, Sayah's work focuses on combating viral infections, including HIV-1.

Latest Patents

David Sayah's latest patents include a groundbreaking invention titled "Polynucleotide encoding a TRIM-cyp polypeptide, compositions thereof, and methods of using same." This invention provides an isolated nucleic acid that encodes a TRIM-cyclophilin A fusion sequence. The TRIMcyp fusion protein is recognized for its activity as an anti-viral agent, specifically targeting HIV-1. The invention encompasses a nucleic acid encoding a polypeptide that exhibits both TRIM and cyclophilin activities. Furthermore, it includes compositions, antibodies that specifically bind to the polypeptide, and vectors and host cells that incorporate the nucleic acid or polypeptide. The methods outlined in the patent aim to treat or prevent viral infections or reduce viral load in subjects by administering the nucleic acid, polypeptide, vector, or composition in effective amounts.

Career Highlights

David Sayah is affiliated with Columbia University, where he continues to advance his research in the field of virology. His work has garnered attention for its potential applications in treating various viral infections, including HIV-1, hepatitis C, and other viral diseases.

Collaborations

Sayah collaborates with notable researchers in his field, including Jeremy Luban, enhancing the impact of his innovative work.

Conclusion

David Sayah's contributions to anti-viral research through his patents and collaborations highlight his commitment to advancing medical science. His innovative approaches have the potential to significantly impact the treatment of viral infections.